iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Lupin bags tentative USFDA approval for DETAF Tablets

31 Jan 2023 , 12:50 PM

Lupin Limited, a leading global pharmaceutical company, has been granted provisional approval from the US Food and Drug Administration (FDA) as part of the US President’s Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application for Dolutegravir, Emtricitabine, and Tenofovir Alafenamide (DETAF) Tablets.

This product will be produced at Lupin’s manufacturing site located in Nagpur, India.

Naresh Gupta, President of API and Global Institution Business at Lupin, expressed his company’s dedication to offering cost-effective and high-quality healthcare solutions to patients in low- and middle-income nations. He expressed his satisfaction with the tentative approval of DETAF by the USFDA, which will significantly boost Lupin’s offerings for treating HIV.

The availability of DETAF, a promising new medication for the treatment of HIV infections, will bring a much-needed boost to low and middle-income nations worldwide.

At around 12.35 PM, Lupin was trading at Rs736.70, up by 0.27% against the previous close of Rs734.70 on NSE. The counter touched an intraday high and low of Rs738.45 and Rs727.30 respectively.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Lupin
  • Lupin Drug
  • Lupin News
  • Lupin Updates
  • Lupin USFDA Approval
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.